Mark Bradley,
Professor of Therapeutic Innovation, Precision Healthcare University Research Institute
Mark received his doctorate from the University of Oxford in 1989, followed by post-doctoral studies at Harvard and returning to the UK as a Royal Society University Research Fellow (University of Southampton). In 1997 he was made a Professor of Combinatorial Chemistry setting up the UK’s Centre for Combinatorial Chemistry. In 2005 he moved to the University of Edinburgh, where he was Director of a £15M Interdisciplinary Research Collaboration in the area of Optical Molecular Imaging (Proteus 2014-2023) and a Doctorial Training Centre (60PhD) in Optical Imaging with Entrepreneurship. In Aug 2023 he moved to Queen Mary University of London as Professor of Therapeutic Innovation and part of the Precision Healthcare university Research Institute. He held an ERC Advanced Grant on “SmartMaterials” for cellular control. He is a co-founder of Ilika Technologies (2004) (which floated on AIMS in 2010), DestiNA Technologies (2010) and Edinburgh Molecular Imaging (2014) and Biocaptiva (2021).
|
|
|
